KR102653599B1 - 질환 치료용 mct4 저해제 - Google Patents
질환 치료용 mct4 저해제 Download PDFInfo
- Publication number
- KR102653599B1 KR102653599B1 KR1020187000674A KR20187000674A KR102653599B1 KR 102653599 B1 KR102653599 B1 KR 102653599B1 KR 1020187000674 A KR1020187000674 A KR 1020187000674A KR 20187000674 A KR20187000674 A KR 20187000674A KR 102653599 B1 KR102653599 B1 KR 102653599B1
- Authority
- KR
- South Korea
- Prior art keywords
- delete delete
- methyl
- compound
- alkyl
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562174685P | 2015-06-12 | 2015-06-12 | |
| US62/174,685 | 2015-06-12 | ||
| PCT/US2016/037213 WO2016201426A1 (en) | 2015-06-12 | 2016-06-13 | Mct4 inhibitors for treating disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20180012852A KR20180012852A (ko) | 2018-02-06 |
| KR102653599B1 true KR102653599B1 (ko) | 2024-04-01 |
Family
ID=57504734
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020187000674A Active KR102653599B1 (ko) | 2015-06-12 | 2016-06-13 | 질환 치료용 mct4 저해제 |
Country Status (11)
| Country | Link |
|---|---|
| US (6) | US10202350B2 (https=) |
| EP (2) | EP3307068B1 (https=) |
| JP (2) | JP6944442B2 (https=) |
| KR (1) | KR102653599B1 (https=) |
| CN (1) | CN107635404B (https=) |
| AU (2) | AU2016277126A1 (https=) |
| BR (1) | BR112017026535B1 (https=) |
| CA (1) | CA2988983A1 (https=) |
| ES (1) | ES2894919T3 (https=) |
| IL (2) | IL256206A (https=) |
| WO (1) | WO2016201426A1 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112017026535B1 (pt) | 2015-06-12 | 2023-12-19 | Vettore, LLC | Composto e composição farmacêutica |
| WO2018111904A1 (en) | 2016-12-12 | 2018-06-21 | Vettore, LLC | Heterocyclic inhibitors of mct4 |
| CA3098189C (en) * | 2018-04-25 | 2025-05-13 | Charles R. Drew University Of Medicine And Science | N-PHENYL-N'-(4-{[6-(1H-IMIDAZOL-1YL)-4-PYRIMIDINYL]AMINO}PHENYL) UREA DERIVATIVES USED AS MCT4 INHIBITORS FOR CANCER TREATMENT |
| TWI823932B (zh) * | 2018-05-11 | 2023-12-01 | 中國大陸商迪哲（江蘇）醫藥有限公司 | 三唑并嘧啶化合物及其在治療癌症中之用途 |
| AR117469A1 (es) | 2018-12-21 | 2021-08-11 | Merck Patent Gmbh | Derivados de alquino disustituidos |
| WO2020234454A1 (en) | 2019-05-23 | 2020-11-26 | Deutsches Krebsforschungszentrum | Combination treatment of cancer targeting energy metabolism and intracellular ph |
| US20210214731A1 (en) * | 2019-10-25 | 2021-07-15 | President And Fellows Of Harvard College | Methods for treating cancer |
| WO2022243574A1 (en) * | 2021-05-21 | 2022-11-24 | Cemm - Forschungszentrum Für Molekulare Medizin Gmbh | 3-(phthalazin-1-yl)benzenesulfonamide-based slc16a3 inhibitors and their therapeutic use |
| CN113929627A (zh) * | 2021-10-19 | 2022-01-14 | 吕梁学院 | 一种宾达利的合成方法 |
| CN113845476B (zh) * | 2021-11-08 | 2024-04-30 | 中国药科大学 | 一种喹诺酮衍生物及其制备方法和用途 |
| WO2024031445A1 (en) * | 2022-08-10 | 2024-02-15 | Vettore, LLC | Methods and processes for the preparation of mct4 inhibitors |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005054852A1 (en) | 2003-11-21 | 2005-06-16 | Astrazeneca Ab | Screening method |
| US20110003874A1 (en) | 2008-03-07 | 2011-01-06 | Aziende Chim. Riun. Ang. Franc. A.C.R.A.F. S.P.A. | Novel 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, cx3cr1 and p40 |
| US20110160248A1 (en) | 2006-02-28 | 2011-06-30 | Xianbo Zhou | Pyrazole compounds and uses thereof |
| WO2013171317A1 (en) | 2012-05-18 | 2013-11-21 | Sanofi | Pyrazole derivatives and their use as lpar5 antagonists |
| WO2014195507A1 (en) | 2013-06-07 | 2014-12-11 | Universite Catholique De Louvain | 3-carboxy substituted coumarin derivatives with a potential utility for the treatment of cancer diseases |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1052111B (it) | 1972-02-29 | 1981-06-20 | Acraf | Acidi i benzil i h indazol 3 carbossilici sostituiti e loro derivati |
| ES2037739T3 (es) | 1986-10-22 | 1993-07-01 | Ciba-Geigy Ag | Derivados del acido 1,5-difenilpirazol-3-carboxilico para la proteccion de plantas de cultivo. |
| FR2742148B1 (fr) | 1995-12-08 | 1999-10-22 | Sanofi Sa | Nouveaux derives du pyrazole-3-carboxamide, procede pour leur preparation et compositions pharmaceutiques les contenant |
| IT1293795B1 (it) | 1997-07-28 | 1999-03-10 | Angelini Ricerche Spa | Farmaco attivo nel ridurre la produzione di proteina mcp-1 |
| TWI339205B (en) | 2006-10-02 | 2011-03-21 | Nat Health Research Institutes | Pyrazole compounds and pharmaceutical composition |
| CN102093341B (zh) | 2009-12-10 | 2013-07-24 | 天津药物研究院 | 吲哚环取代的吡唑羧酸类内皮素受体拮抗剂及其制备方法和用途 |
| JP2013540995A (ja) * | 2010-08-18 | 2013-11-07 | カリス ライフ サイエンシズ ルクセンブルク ホールディングス エス．アー．エール．エル． | 疾患に対する循環バイオマーカー |
| US20130190324A1 (en) | 2011-12-23 | 2013-07-25 | The Regents Of The University Of Colorado, A Body Corporate | Topical ocular drug delivery |
| EP2804852A2 (en) | 2012-01-20 | 2014-11-26 | Regents Of The University Of Minnesota | Therapeutic compounds |
| GB2523211B (en) | 2012-01-27 | 2020-03-18 | Univ Jefferson | MCT protein inhibitor-related prognostic and therapeutic methods |
| PE20151140A1 (es) | 2012-08-16 | 2015-08-07 | Janssen Pharmaceutica Nv | Pirazoles sustituidos como bloqueadores del canal de calcio tipo n |
| CN106794264B (zh) | 2014-06-10 | 2021-03-23 | 3B制药有限公司 | 包含神经降压肽受体配体的缀合物及其用途 |
| DE202015003905U1 (de) | 2015-06-05 | 2016-09-12 | Rudolf King | Methode zur Übermittlung und Differenzierung von Verfassungszuständen während und nach Auslösen eines persönlichen Notfallsystems oder Systems zur Mitteilung an ein soziales Notfallsystem oder Systems zur Mitteilung an ein soziales Notfall-Netzwerk |
| US20160362056A1 (en) | 2015-06-11 | 2016-12-15 | Cequent Performance Products Inc. | Roof rack crossbar assembly |
| BR112017026535B1 (pt) | 2015-06-12 | 2023-12-19 | Vettore, LLC | Composto e composição farmacêutica |
| WO2018111904A1 (en) | 2016-12-12 | 2018-06-21 | Vettore, LLC | Heterocyclic inhibitors of mct4 |
-
2016
- 2016-06-13 BR BR112017026535-4A patent/BR112017026535B1/pt active IP Right Grant
- 2016-06-13 JP JP2018516405A patent/JP6944442B2/ja active Active
- 2016-06-13 AU AU2016277126A patent/AU2016277126A1/en not_active Abandoned
- 2016-06-13 US US15/180,623 patent/US10202350B2/en active Active
- 2016-06-13 EP EP16808515.7A patent/EP3307068B1/en active Active
- 2016-06-13 CN CN201680034104.1A patent/CN107635404B/zh active Active
- 2016-06-13 ES ES16808515T patent/ES2894919T3/es active Active
- 2016-06-13 EP EP21191357.9A patent/EP3942934A1/en active Pending
- 2016-06-13 KR KR1020187000674A patent/KR102653599B1/ko active Active
- 2016-06-13 WO PCT/US2016/037213 patent/WO2016201426A1/en not_active Ceased
- 2016-06-13 CA CA2988983A patent/CA2988983A1/en active Pending
-
2017
- 2017-12-10 IL IL256206A patent/IL256206A/en unknown
-
2018
- 2018-12-17 US US16/222,964 patent/US20190112274A1/en not_active Abandoned
-
2020
- 2020-09-23 US US17/030,243 patent/US11155522B2/en active Active
- 2020-10-22 IL IL278247A patent/IL278247B/en unknown
-
2021
- 2021-02-12 AU AU2021200919A patent/AU2021200919B2/en active Active
- 2021-06-22 JP JP2021102860A patent/JP2021152056A/ja active Pending
- 2021-09-22 US US17/481,660 patent/US11724989B2/en active Active
-
2023
- 2023-06-19 US US18/337,313 patent/US12187682B2/en active Active
-
2024
- 2024-11-25 US US18/958,610 patent/US20250257039A1/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005054852A1 (en) | 2003-11-21 | 2005-06-16 | Astrazeneca Ab | Screening method |
| US20110160248A1 (en) | 2006-02-28 | 2011-06-30 | Xianbo Zhou | Pyrazole compounds and uses thereof |
| US20110003874A1 (en) | 2008-03-07 | 2011-01-06 | Aziende Chim. Riun. Ang. Franc. A.C.R.A.F. S.P.A. | Novel 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, cx3cr1 and p40 |
| WO2013171317A1 (en) | 2012-05-18 | 2013-11-21 | Sanofi | Pyrazole derivatives and their use as lpar5 antagonists |
| WO2014195507A1 (en) | 2013-06-07 | 2014-12-11 | Universite Catholique De Louvain | 3-carboxy substituted coumarin derivatives with a potential utility for the treatment of cancer diseases |
Non-Patent Citations (3)
| Title |
|---|
| European Journal of Medicinal Chemistry, (2010) Vol. 45, pp. 1173-1180 |
| Journal of Enzyme Inhibition and Medicinal Chemistry, (2011) Vol. 26(2), pp. 222-230 |
| Journal of Medicinal Chemistry, (2008) Vol. 51, pp. 142-147 |
Also Published As
| Publication number | Publication date |
|---|---|
| US12187682B2 (en) | 2025-01-07 |
| US20210009524A1 (en) | 2021-01-14 |
| EP3942934A1 (en) | 2022-01-26 |
| US20250257039A1 (en) | 2025-08-14 |
| JP2018516994A (ja) | 2018-06-28 |
| US20240101518A1 (en) | 2024-03-28 |
| NZ738078A (en) | 2021-11-26 |
| BR112017026535A2 (pt) | 2018-08-14 |
| AU2021200919A1 (en) | 2021-03-04 |
| US20160362378A1 (en) | 2016-12-15 |
| ES2894919T3 (es) | 2022-02-16 |
| CN107635404A (zh) | 2018-01-26 |
| US11724989B2 (en) | 2023-08-15 |
| IL256206A (en) | 2018-02-28 |
| AU2021200919B2 (en) | 2022-06-30 |
| AU2016277126A1 (en) | 2017-12-14 |
| HK1253239A1 (en) | 2019-06-14 |
| JP6944442B2 (ja) | 2021-10-06 |
| EP3307068B1 (en) | 2021-08-25 |
| US11155522B2 (en) | 2021-10-26 |
| CA2988983A1 (en) | 2016-12-15 |
| WO2016201426A1 (en) | 2016-12-15 |
| CN107635404B (zh) | 2021-09-28 |
| BR112017026535B1 (pt) | 2023-12-19 |
| US20220251045A1 (en) | 2022-08-11 |
| EP3307068A4 (en) | 2018-12-26 |
| EP3307068A1 (en) | 2018-04-18 |
| JP2021152056A (ja) | 2021-09-30 |
| US20190112274A1 (en) | 2019-04-18 |
| US10202350B2 (en) | 2019-02-12 |
| KR20180012852A (ko) | 2018-02-06 |
| IL278247B (en) | 2021-12-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102653599B1 (ko) | 질환 치료용 mct4 저해제 | |
| EP3551625B1 (en) | Heterocyclic inhibitors of mct4 | |
| JP7601788B2 (ja) | チロシンキナーゼの複素環式阻害剤 | |
| ES2788449T3 (es) | Inhibidores de GLS1 para tratar enfermedades | |
| KR20210003764A (ko) | 전사 활성화 단백질의 이미다조피페라진 억제제 | |
| US20160002248A1 (en) | Gls1 inhibitors for treating disease | |
| IL301707A (en) | Imidazopiperazine inhibitors of transcription-activating proteins | |
| WO2022072647A1 (en) | Imidazopiperazine inhibitors of transcription activating proteins | |
| HK40066026A (en) | Mct4 inhibitors for treating disease | |
| HK1253239B (en) | Mct4 inhibitors for treating disease | |
| HK40117469A (en) | Heterocyclic inhibitors of mct4 | |
| HK40015139B (en) | Heterocyclic inhibitors of mct4 | |
| HK40015139A (en) | Heterocyclic inhibitors of mct4 | |
| NZ738078B2 (en) | Mct4 inhibitors for treating disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20180109 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| A201 | Request for examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20210611 Comment text: Request for Examination of Application |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20231012 Patent event code: PE09021S01D |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20240109 |
|
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20240328 Patent event code: PR07011E01D |
|
| PR1002 | Payment of registration fee |
Payment date: 20240328 End annual number: 3 Start annual number: 1 |
|
| PG1601 | Publication of registration |